FLT3 and acute myeloid leukemia: The 2017 European LeukemiaNet (ELN) recommendation for risk-stratification of AML [24] (Table 3) is the most widely used model in current clinical practice since it incorporates cytogenetic changes and gene mutation status, including FLT3-ITD allelic ratio, into the risk classification which largely enhances the stratification power compared with the 2010 version of the ELN recommendations [25].